To investigate the effects of LRRC8A or LRRC8D defects on Pt drug sensitivity in HR-deficient tumors, we generated CRISPR/Cas9 KOs in cell lines derived from a genetically engineered mouse model for hereditary BRCA1-mutated breast cancer (25). This evidence concerns the gene BRCA1 and breast cancer.